Reduction of Allogeneic Blood Transfusion in Surgery Patients
EPOETIN® is indicated for the treatment of anemic patients (hemoglobin > 10 to ≤ 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions.18-20 EPOETIN® is indicated for patients at high risk for perioperative transfusions with significant, anticipated blood loss. EPOETIN® is not indicated for anemic patients who are willing to donate autologous blood (see BOXED WARNINGS and DOSAGE AND ADMINISTRATION).
Treatment of Anemia in Zidovudine-treated HIV-infected Patients
EPOETIN® is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. EPOETIN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients.
EPOETIN® is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.
EPOETIN®, at a dose of 100 Units/kg TIW, is effective in decreasing the transfusion requirement and increasing the red blood cell level of anemic, HIV-infected patients treated with zidovudine, when the endogenous serum erythropoietin level is ≤ 500 mUnits/mL and when patients are receiving a dose of zidovudine ≤ 4200 mg/week.